Promethazine and Neoplasm progression - a phase IV clinical study of FDA data

Summary:

Neoplasm progression is reported as a side effect among people who take Promethazine (promethazine hydrochloride), especially for people who are female, 60+ old, also take Ibrance, and have Breast cancer female.

The phase IV clinical study analyzes which people have Neoplasm progression when taking Promethazine. It is created by eHealthMe based on reports of 31,259 people who have side effects when taking Promethazine from the FDA, and is updated regularly.

What is Promethazine?

Promethazine has active ingredients of promethazine hydrochloride. It is often used in nausea. eHealthMe is studying from 32,300 Promethazine users. Check the latest studies of Promethazine.

What is Neoplasm progression?

Neoplasm progression (growth of tumour) is found to be associated with 1,065 drugs and 915 conditions by eHealthMe. Check the latest studies of Neoplasm progression.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 19, 2026

31,259 people reported to have side effects when taking Promethazine.
Among them, 68 people (0.22%) have Neoplasm progression.

Could Promethazine cause Neoplasm progression?

Among these 68 people:

What is the gender of people who have Neoplasm progression when taking Promethazine? *

female: 70.77 %
male: 29.23 %

What is the age of people who have Neoplasm progression when taking Promethazine? *

What are other drugs people take besides Promethazine? *

What are other side effects people have besides Neoplasm progression? *

Fatigue (feeling of tiredness): 25 people, 36.76%
Pain: 14 people, 20.59%
Rashes (redness): 13 people, 19.12%
Back Pain: 13 people, 19.12%
Diarrhea: 13 people, 19.12%
Headache (pain in head): 12 people, 17.65%
Dyspnea (difficult or laboured breathing): 11 people, 16.18%
Appetite - Decreased (decreased appetite occurs when you have a reduced desire to eat): 10 people, 14.71%
Taste - Impaired: 10 people, 14.71%
Weakness: 10 people, 14.71%

What are the existing conditions these people have? *

Breast Cancer Female: 13 people, 19.12%
Breast Cancer Metastatic: 10 people, 14.71%
Renal Cell Carcinoma (a kidney cancer): 8 people, 11.76%
Stress And Anxiety: 8 people, 11.76%
Pain: 6 people, 8.82%
Metastases To Bone (cancer spreads to bone): 5 people, 7.35%
Metastatic Renal Cell Carcinoma (spreadable kidney cell tumour): 4 people, 5.88%
Cough: 4 people, 5.88%
Blood Pressure Abnormal: 3 people, 4.41%
Blood Pressure Fluctuation: 3 people, 4.41%

* Approximation only. Some reports may have incomplete information.

Do you take Promethazine and have Neoplasm progression?

- Check whether Neoplasm progression is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Promethazine:

Promethazine (32,300 reports)

Browse all side effects of Promethazine:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Neoplasm progression:

Neoplasm progression (1,065 drugs)

Browse all the conditions that are associated with Neoplasm progression:

Neoplasm progression (915 conditions)

Related publications that referenced our studies

Teimoory M, Arefi M, Behnoush B, Bastani B, "Promethazine and Treatment Refractory Agitation in Clonidine Toxicity", International Journal of Medical Toxicology and Forensic Medicine, 2013 Mar .
Teimoory M, Arefi M, Behnoush B, Bastani B, "Promethazine and Treatment Refractory Agitation in Clonidine Toxicity", International Journal of Medical Toxicology and Forensic Medicine, 2013 Mar .

How the study uses the data?

The study uses data from the FDA. It is based on promethazine hydrochloride (the active ingredients of Promethazine) and Promethazine (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.